option holders, page-11

Hi Hoofa,

Whatever GSK might be spending on R&D for Oral Healthcare we probably couldn't match it so I'm just grateful that we as s/holders haven't been asked to put out hands in our own pockets for over 2 years now. For a young Biotech company with or without revenue, this is very rare. OBJ is the ONLY Australian company to be collaborating with one of the world's top 3 market leaders within this segment and it is common knowledge within the Pharma world that GlaxoSmithKline only seek out partners whom they consider to contribute the most innovative science.

When it comes down to the credibility of OBJ's science who would you prefer to believe, our market or GlaxoSmithKine?

From GSK's Annual Report - 2010
Oral healthcare grew 6% to £1.6 billion, led by a strong performance from Sensodyne, which continued as the fastest growing toothpaste in the world, a position it has held for the last 5 years. This is a remarkable record for a brand in its 50th year. Following our 2010 launch in India, we now market Sensodyne in 124 countries. However, Aquafresh sales declined slightly. Biotene, the dry mouth treatment acquired in 2008, grew strongly.

The consumer healthcare industry is subject to national regulation comparable to that for prescription medicines for the testing, approval, manufacturing, labelling and marketing of products. High standards of technical appraisal frequently involve a lengthy approval process before a new product may be launched.

Moreover, we won't be waiting another 3.5 years for anyone to be telling us "we are nearly there". Our Directors have now made this very clear imo:

(a) 6 million performance rights to vest subject to the execution of an agreement to design and develop commercial product(s) utilising the Company’s technologies (Milestone 1);
(b) 6 million performance rights to vest subject to the satisfaction of the regulatory requirements necessary for the Company to offer a product of its own design and development to the market either directly or through partners (Milestone 2); and
(c) 6 million performance rights to vest subject to the commercial release of a product utilising the Company’s technology (Milestone 3)

I certainly wouldn't be taking the 3 year time-line too seriously either - No company sets out a dead-line for performance rights as a challenge - We can cut that in half from whatever date it started and be rest-assured it still remains in very safe territory.
___

Hi Jaybay,

The old saying, "The future belongs to those who create it" - doesn't quite fit in Nikola Tesla's case does it...

Nikola Tesla once said of Thomas Edison:

"If Edison had a needle to find in a haystack, he would proceed at once with the diligence of the bee to examine straw after straw until he found the object of his search.. I was a sorry witness of such doings, knowing that a little theory and calculation would have saved him ninety per cent of his labor."

It kind of reflects the world's dilema with carbon dioxide emissions... why this remains such a hot debated topic when the solution was invented 120 years ago - At the current rate of population growth the monopoly men must sooner rather than later devise their plans for this untapped free source of green energy... but for now I'm probably just going off topic ;)
___

Hi Southoz,

How long would you expect the full development of a "smart" patch technology should take? A product composed of any combination of a drug and a device; a biological product and a device; a drug and a biological product; or a drug, device, and a biological product is regulated by the FDA Under 21 CFR 3.2 (e), as a combination product. (sourced from FDA website)

I'm not aware of "e-skin" ever appearing in past ASX announcements from OBJ, however you are quite right in that the term "Smart Patch" has been used in reference to onging developments with Dermaportation technology. I believe the term, "Smart Patch" was first formally announced in July 2005 - six and half years ago.

Vyteris claimed the honor of developing the first FDA approved active "smart" patch which I'm sure you must agree as a believer in traditional and not these type of complementary or alternative technologies, was a significant achievement by them and their collaborators.

I believe Vyteris first started developing their original version of a "smart" patch in the 1980's?

I also believe Mark Prausnitz from Georgia Tech who will be referenced somewhere in this 2006 paper became an integral part of the Vyteris team in 2010 to integrate Georgia Tech's thermal ablation and fabrication technologies for extending the range of therapeutic's that Vyteris active "smart" patch will be able to deliver.
___